Life Sciences Tools and Services

West Pharmaceutical

Barclays Upgrades Cigna to Overweight, Raises Target to $400, Driving Stock Price Higher

Gates Foundation Sells All Microsoft Shares in Q1, Establishes Position in WST

Stephens Reaffirms Overweight Rating on West Pharmaceutical Services with $360 Target Price; Company Beats Q1 Earnings and Authorizes $1B Buyback

CSL Services Operations Steadily Recover After Cyber Attack, Shares Rise Over 1%

W. R. Grace Executives Sell Company Stocks

West Pharmaceutical released FY2026 Q1 earnings on April 23 Pre-Market EST, actual revenue USD 844.9 M (forecast USD 779.37 M), actual EPS USD 1.92 (forecast USD 1.6675)

West Pharmaceutical Services Reports Q1 Net Sales Up 21% and Raises Full-Year Revenue Guidance

West Pharmaceutical to Release FY2026 Q1 Earnings on April 23 Pre-Market EST, Forecast Revenue USD 779.37 M, EPS USD 1.6675

West Pharmaceutical Services Releases 2025 Annual Report

West Pharmaceutical released FY2025 Q4 earnings on February 12 Pre-Market EST, actual revenue and EPS data unavailable

West Pharmaceutical released FY2025 earnings on February 12 Pre-Market (EST), actual revenue USD 3.074 B (forecast USD 3.064 B), actual EPS USD 6.79 (forecast USD 6.8815)

West Pharmaceutical to release FY2025 Q4 earnings on February 12 Pre-Market EST, forecast revenue USD 795.7 M, EPS USD 1.834

West Pharmaceutical Services to Release Earnings Report

West Pharmaceutical released FY2025 9 Months Earnings on October 23 Pre-Market (EST), actual revenue USD 2.269 B, actual EPS USD 4.97

West Pharmaceutical released FY2025 Q3 earnings on October 23 Pre-Market (EST), actual revenue USD 804.6 M (forecast USD 789.89 M), actual EPS USD 1.92 (forecast USD 1.7385)

West Pharmaceutical to Release FY2025 Q3 Earnings on October 23 Pre-Market (EST), Forecast Revenue USD 788.38 M, EPS USD 1.6307

West Pharmaceutical released FY2025 Semi-Annual earnings on July 24 Pre-Market EST, actual revenue USD 1.465 B, actual EPS USD 3.05

West Pharmaceutical released FY2025 Q2 earnings on July 24 Pre-Market EST, actual revenue USD 766.5 M (forecast USD 730.07 M), actual EPS USD 1.82 (forecast USD 1.5466)

West Pharmaceutical to release FY2025 Q2 earnings on July 24 Pre-Market EST, forecast revenue USD 725.28 M, EPS USD 1.4699

West Pharmaceutical Services Transitions from Pandemic Growth Phase to Strong Free Cash Flow Era

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

West Pharmaceutical Servs shares are trading higher after Barclays upgraded the stock from Equal-Weight to Overweight rating and raised its price target from $310 to $400.

benzinga_article

Barclays

Wall Street analysts upgraded five stocks on Tuesday. UBS upgraded Arthur J. Gallagher (AJG) to Buy with a $250 target. Sidoti & Co. upgraded Brady Corp (BRC) to Buy with a $103 target. GLJ Research upgraded Cleveland-Cliffs (CLF) to Hold with a $15.01 target. JP Morgan upgraded PAR Technology (PAR) to Neutral with a $16 target. Barclays upgraded West Pharmaceutical Services (WST) to Overweight with a $400 target.

Cleveland Cliffs

PAR Tech

Brady

Arthur J Gallagher

This Brady Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

West Pharmaceutical Services Inc. (WST) stock rose 1.67% to $319.75, outperforming competitors Abbott Laboratories, Becton Dickinson, and Baxter International on a mixed trading day. The S&P 500 gained 0.30%, while the Dow Jones fell 0.16%. WST closed 3.36% below its 52-week high of $330.88. Trading volume was below the 50-day average.

MarketWatch Automated

West Pharmaceutical Services Inc. Stock Outperforms Competitors On Strong Trading Day

West Pharmaceutical Services (WST) stock closed at $314.50, showing strong long-term returns but recent short-term consolidation. Analysis indicates the stock is overvalued, trading at a P/E of 40.9x against a fair value estimate of 21.2x. A Discounted Cash Flow model suggests an intrinsic value of $202.45, significantly below the current price, implying limited upside despite robust earnings growth and margins.

Simplywall

A Look At West Pharmaceutical Services (WST) Valuation After Recent Share Price Consolidation

MSFX

MSFD

MSFU

MSFL

MSFO

MSFY

The Bill & Melinda Gates Foundation Trust sold its entire Microsoft stake in Q1 and initiated a position in West Pharmaceutical Services (WST). WST, a leading manufacturer of drug delivery systems, has raised dividends for 32 years and is projected to see 14-15% annualized earnings growth through 2027. Despite a low yield, the stock's consistent dividend history and growth forecasts make it an attractive long-term investment.

nasdaq

T-Rex 2X Long Microsoft Daily Target ETF

Direxion Daily MSFT Bear 1x Shares

Direxion Daily MSFT Bull 2X Shares

GraniteShares 2x Long MSFT Daily ETF

YieldMax MSFT Option Income Strategy ETF

Kurv Yield Premium Strategy Microsoft MSFT ETF

Microsoft

Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion

West Pharmaceutical Services (WST) shares fell 1.31% to $312.17 on Tuesday, underperforming the broader market and key competitors like Abbott Laboratories and Baxter International. This marks the second consecutive day of losses for WST, which remains 5.65% below its 52-week high. Trading volume was notably lower than the 50-day average.

S&P 500

Dow Jones Industrial Average

Abbott Laboratories

Becton Dickinson and

Baxter

Factset Research

West Pharmaceutical Services Inc. Stock Underperforms Tuesday When Compared To Competitors

Stephens reiterated an 'overweight' rating on West Pharmaceutical Services (WST) with a $360 price target, indicating 13.97% upside. Other analysts like Evercore, Morgan Stanley, and Deutsche Bank also maintain positive ratings or raised targets. WST recently beat Q1 earnings estimates with $2.13 EPS and $844.9M revenue. The company authorized a $1B share buyback program. Recent insider sales by CAO Chad Winters and VP Annette Favorite were disclosed.

Market Beat

Morgan Stanley

Deutsche Bank AG

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

West Pharmaceutical Services' (WST) "Overweight" Rating Reiterated at Stephens

West Pharmaceutical(WST.US)